LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We identified duplication of Chr1q, duplication of Chr5p harboring the TERT genomic locus and mutations of TERT promoter as distinctive features of DM PTCs.
|
29416733 |
2018 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The combination of BRAF and TERT promoter mutations could classify PTCs into four distinct risk groups with decreasing aggressiveness as follows: coexisting BRAF and TERT > TERT alone=BRAF alone > no mutations.
|
28666074 |
2017 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in TERT promoter have been detected in the more aggressive papillary thyroid cancers (PTCs).
|
30661164 |
2019 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutations were seen more frequently in advanced cancers with BRAF/RAS mutations compared to those that were BRAF/RAS wild-type (ATC + PDTC, 67.3 vs 24.1%; P < 10(-4)), whereas BRAF-mutant PTCs were less likely to have TERT promoter mutations than BRAF wild-type tumors (11.8 vs 50.0%; P = .04).
|
23833040 |
2013 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this work, a DNA microarray-based resonance light scattering (RLS) assay has been developed for multiplexed detection of papillary thyroid carcinoma (PTC) related mutation points including BRAF<sup>V600E</sup> (t1m), NRAS codon 61 (t2m), TERT promoter g.1295228 (t31m) and TERT promoter g.1295250 (t32m) with high sensitivity and selectivity by the attachment of polyvalent ssDNA modified 13 nm gold nanoparticles (ssDNAs@GNPs) followed by silver deposition for signal enhancement.
|
29362729 |
2018 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The most common C228T TERT promoter mutation was identified in 2 PTC cases co-existing with the BRAF mutation.
|
30361901 |
2018 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Coexisting BRAF V600E and TERT promoter mutations have a robust synergistic impact on the aggressiveness of PTC, including a sharply increased tumor recurrence and patient mortality, while either mutation alone has a modest impact.
|
26733501 |
2016 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the incidence of TERT promoter mutations and TERT protein expression and their association with clinicopathological outcomes in a large cohort of PTC samples using direct sequencing technology and immunohistochemistry.
|
29266240 |
2018 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The TERT promoter mutation was detected in 18% of PTC patients (13/74).
|
26727717 |
2016 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A unique prognostic role of the genetic duet of BRAF V600E and TERT promoter mutations in papillary thyroid cancer (PTC) has been recently established, but the role of RAS mutation in this genetic interplay remains to be established.
|
27875244 |
2017 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutations are closely associated with aggressive clinicopathological characteristics and poorer prognosis in PTC.
|
27833153 |
2016 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We showed that the ATC/DM-PTC group had an overall mutational load higher than ctrl-PTCs and that ATCs and DM-PTCs are characterized by a different genetic background, with the exception of mutations in the TERT promoter that were overrepresented in both ATCs (61.1%) and DM-PTCs (48.2%) vs non-aggressive ctrl-PTCs (7.6%).
|
30400028 |
2018 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Exclusion of mutations in TP53 and the TERT promoter could be considered as an adjunct tool when assessing papillary thyroid cancer with focal pleomorphism.
|
29976183 |
2018 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutation (C228T) was identified in 2 ATC and one HVPTC patient.
|
28423545 |
2017 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutations (any type) were detected in 13.5% (77/568) of PTC cases with known BRAF status.
|
31305897 |
2019 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ultrasonographic prediction of highly aggressive telomerase reverse transcriptase (TERT) promoter-mutated papillary thyroid cancer.
|
28616852 |
2017 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While TERT promoter mutations were rare and subclonal in PTCs, they were clonal and highly prevalent in advanced cancers.
|
26878173 |
2016 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we assessed the impact of the combination of the TERT promoter/BRAF mutations and Ki-67 labeling index (LI) as a prognostic marker in PTC patients.
|
28150740 |
2017 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
C228T mutation of the TERT promoter was reported in 10% of the papillary carcinomas (PTC) series.
|
25951319 |
2016 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aims to evaluate the frequencies of BRAF and TERT promoter mutations and to examine their significance in non-radiation-associated pediatric PTCs in Japan.
|
28176151 |
2017 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutations were likely to occur in a sub-clonal manner in our PTC cohort.
|
29144541 |
2018 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Coexisting BRAF<sup>V600E</sup> and TERT promoter mutations were detected in a subgroup of aggressive PTCs (12%).
|
30501571 |
2019 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To data, there is no high-level evidence approving the association of TERT promoter mutation and aggressive clinical behaviours in PTC.
|
26732020 |
2016 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT Promoter Mutation in an Aggressive Cribriform Morular Variant of Papillary Thyroid Carcinoma.
|
27688081 |
2017 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, molecular testing of BRAF<sup>V600E</sup> and TERT promoter mutations together is useful in assessing risk stratification of PTC.
|
28181854 |
2017 |